Clinical results of long-term slow-release lanreotide treatment of acromegaly

European Journal of Clinical Investigation

Volumn 27, Issue 4, 1997, Pages 277-284

  Giusti, M ^a,h   Ciccarelli, E ^b   Dallabonzana, D ^c   Delitala, G ^d   Faglia, G ^e   Liuzzi, A ^f   Gussoni, G ^g   Giordano Disem, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g IPSEN   (France)

^h DISEM   (Italy)

Author keywords

Acromegaly; Effectiveness; GH IGF I; Lanreotide SR; Tolerability

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030891582     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1190659.x     Document Type: Article

References (37)

1. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-402.
2. Bates AS, Van't Hoff W, Jones JM, Clayton RN. Does treament of acromegaly affect life expectancy? Metabolism 1995;44 (Suppl. 1):1-5.
3. Serri O, Somma R, Comtois R et al. Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab 1985;61:1185-9.
4. Klibanski A, Zervas NT. Diagnosis and management of hormone secreting pituitary adenomas. N Engl J Med 1991;324:822-31.
5. Ho KKY, Weissberger AJ Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol 1994;41:75-83.
6. Barreca A, Ciccarelli E, Minuto F, Bruzzi P, Giordano G, Camanni F. Insulin-like growth factor 1 and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol 1989;120:629-35.
7. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 1990;71:391-7.
8. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients: a multicenter Italian study. Eur J Endocrinol 1995;133:430-9.
9. Newman CB, Melmed S, Snyder PJ et al. Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients. A clinical research center study. J Clin Endocrinol Metab 1995;80:2768-75.
10. Harris AG, Kokons SP, Ezzat S. Continuous vs. intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. J Clin Pharmacol 1995;35:59-71.
11. Lancranjan I, Bruns C, Grass P et al. Sandostatin LAR: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995;44 (Suppl. 1):18-26.
12. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, Jervell J. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-7.
13. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard M. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-72.
14. Heron I, Thomas F, Dero M et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analogue BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-7.
15. Morange I, De Boisvilliers F, Chanson P et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994;79:145-51.
16. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 1994;130:229-34.
17. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20-6.
18. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 1995;132:320-5.
19. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow-release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab 1996;81:2089-97.
20. Gancel A, Vuillermet P, Lengrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH secreting pituitary adenomas. Clin Endocrinol 1994;40:421-8.
21. Ezzat S, Snyder PJ, Young WF et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711-8.
22. Semer M, Faria ACS, Nery M et al. Growth hormone pulsatility in active and cured acromegalic subjects. J Clin Endocrinol Metab 1995;80:3767-70.
23. Yoshida T, Shimatsu A, Sakane N, Hizuka N, Horikawa R, Tanaka T. Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels. J Clin Endocrinol Metab 1996;81:310-3.
24. Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Ann Intern Med 1990;112:173-81.
25. Ezzat S, Redelmeier DA, Gnehm M, Harris AG. A prospective multicenter octreotide dose response study in the treatment of acromegaly. J Endocrinol Invest 1995;18:364-9.
26. Greeman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 1994;79:724-9.
27. Miller G, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995;80:1386-92.
28. Moyse E, Le Dafniet M, Epelbaum J et al. Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 1985;61:98-103.
29. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SWJ. Relative potencies of the somatostatin analogs octreotide. BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 1994;134:301-6.
30. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-42.
31. Ezzat S, Ren SG, Braunstein GD. Octreotide stimulates insulin-like growth factor-binding protein-I: a potential pituitary independent mechanism for drug action. J Clin Endocrinol Metab 1992;75:1459-63.
32. Wolthers T, Grofte T, Flyvbjerg A et al. Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog. J Clin Endocrinol Metab 1994;78:141-4.
33. Barreca A, Cariola P, Ponzani P et al. Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clin Endocrinol 1995;42:161-7.
34. Merola B, Cittadini A, Colao A et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1995;77:790-3.
35. Tauber JP, Poncet MF, Harris AG et al. The impact of continuous subcutaneous infusion of octreotide on gallstone in acromegalic patients. J Clin Endocrinol Metab 1995;80:3262-6.
36. Montini M, Gianola D, Pagani MD et al. Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol 1994;40:401-6.
37. Frohman LA. Acromegaly: what constitutes optimal therapy? (editorial). J Clin Endocrinol Metab 1996;81:443-5.